- Arcellx expects to launch its lead asset, **Anito-cel**, a BCMA-directed CAR-T for multiple myeloma, in **mid to late 2026**, targeting a **$3.5 billion market** in the fourth-line+ setting.  **[1786205_2137354_3]** **[1786205_2137354_4]** 
- The company reported strong efficacy data for Anito-cel from the iMMagine-1 study at EHA, including a **66% PFS rate at 18 months** and a **low 90s% MRD negativity rate**, with a differentiated safety profile showing **no cases of delayed neurotoxicity or immune-related enterocolitis** with at least four months of follow-up.  **[1786205_2137354_1]** **[1786205_2137354_2]** 
- Arcellx ended Q2 with **$538 million in cash**, providing a runway that funds the company **into 2028**, covering the Anito-cel launch and substantial post-launch operations.  **[1786205_2137354_7]** 
- The company is confident in the regulatory path for Anito-cel, citing the unmet need in multiple myeloma related to safety issues and access, and plans to file the Biologics License Application (BLA) **late this year into early next year**.  **[1786205_2137354_2]** **[1786205_2137354_3]**

Arcellx (ACLX)